Computational biologist. I reconstruct how tumors evolve, diversify, and spread — from bulk, long-read, and single-cell sequencing data.
On the job market. Available from December 2026 for research faculty and industry research positions.
I work on how tumors evolve — how they restructure their genomes and amplify oncogenes, diversify into genetically distinct subpopulations within a single patient, and spread from one organ to another. None of it is observed directly. It has to be reconstructed from sequencing data, and I build the methods that do the reconstructing.
My current focus is focal oncogene amplification: extrachromosomal DNA and breakage–fusion–bridge cycles, two of the most aggressive routes to drug resistance. I work across bulk whole-genome, long-read, and single-cell sequencing, on patient cohorts in lung, prostate, breast, and ovarian cancer and in acute myeloid leukemia.
PhD candidate at the University of Illinois Urbana-Champaign, advised by Mohammed El-Kebir. Previously B.Sc. at the Bangladesh University of Engineering and Technology, and lecturer at Southeast University, Dhaka.
Some of the most aggressive tumors amplify oncogenes not by duplicating them in place, but by restructuring the genome — spinning copies off onto circular extrachromosomal DNA, or repeatedly breaking and refusing chromosome ends in breakage–fusion–bridge cycles. Because ecDNA carries no centromere, it segregates randomly at mitosis, letting a tumor swing its oncogene dosage far faster than chromosomal inheritance allows — much of why these tumors escape treatment.
Both mechanisms leave repetitive signatures that conventional copy-number callers cannot resolve. I develop methods to reconstruct them from bulk and single-cell DNA sequencing, trace how they evolve under therapy, and quantify their contribution to cancer cell fitness.
Metastasis is what makes cancer lethal, but the route a tumor took through the body — which site seeded which, and in what order — is never observed. It has to be read back out of the clonal phylogeny, and whether metastases seed each other or all descend from the primary changes how the disease is understood and treated.
Existing methods report one "most likely" route, hiding how much ambiguity the data actually leaves. MACH2 recovers every migration history the data supports equally well. It outperforms existing methods on simulated and real lung, prostate, breast, and ovarian cancer cohorts. Published in Nature Methods.
An antibody response is evolution compressed into weeks: B cells mutate their antibody genes, get selected on binding affinity, and switch isotype to change the antibody's function. Reconstructing that history matters for vaccine response, autoimmunity, and B cell malignancies.
Most lineage methods read only the mutations and discard the isotype switches. TRIBAL uses both, from single-cell RNA sequencing data, recovering the expected trends of affinity maturation in a model system. Published in Cell Genomics.
Enumerates the full space of optimal migration histories for metastatic cancers via integer linear programming.
Isotype-aware reconstruction of B cell clonal lineage trees from single-cell sequencing data.